Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00294762 · ClinicalTrials.gov registry record · Phase 2
Erlotinib (Tarceva) as a Single Agent or Intercalated With Combination Chemotherapy in Patients With EGFR Positive NSCLC
A Phase 2 study, sponsored by OSI Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 143
- Enrollment target
NCT00294762 is a Phase 2 study that has completed, run by OSI Pharmaceuticals. The registered enrollment target is 143 participants.
The verdict
NCT00294762, a Phase 2 study, has completed, sponsored by OSI Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 143 participants
- Enrollment target
Study Summary
This will be the first prospective study where patients will be selected on the basis of two measures of the epidermal growth factor receptor (EGFR) pathway. The study will assess prospectively the efficacy of erlotinib as a single agent or intercalated with chemotherapy in highly selected patients with EGFR overexpression and/or EGFR amplification.
Interventions
- DRUG carboplatin
- DRUG paclitaxel
- DRUG Tarceva
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 143 participants |
| Start Date | 2006-01 |
| Est. Completion | 2009-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00294762
The ClinicalTrials.gov registry entry for NCT00294762 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 143 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is OSI Pharmaceuticals, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which carboplatin is the first listed.
NCT00294762 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00294762 about?
NCT00294762 is a clinical study titled "Erlotinib (Tarceva) as a Single Agent or Intercalated With Combination Chemotherapy in Patients With EGFR Positive NSCLC". This will be the first prospective study where patients will be selected on the basis of two measures of the epidermal growth factor receptor (EGFR) pathway. The study will assess prospectively the efficacy of erlotinib as a single agent or intercalated with chemotherapy in highly selected patients ...
What is the current status of trial NCT00294762?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 143 participants. The study started on 2006-01. Estimated completion is 2009-03.
What interventions are being tested in trial NCT00294762?
The interventions under investigation include: carboplatin (DRUG), paclitaxel (DRUG), Tarceva (DRUG).
Who is sponsoring clinical trial NCT00294762?
This trial is sponsored by OSI Pharmaceuticals, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.